BridgeBio Pharma, Inc. (BBIO) earnings
BBIO earnings moved a median of -0.09% by the close. Quarterly and annual BBIO reports and results, each read against the price at its own news timestamp. Back to the BBIO overview →
24 measured BBIO earnings events.
Where these BBIO earnings landedvs 24 measured BBIO earnings reactions
| Middle 50% of BBIO earnings reactions | -2.35% to +0.77% |
|---|---|
| Median reaction (to close) | -0.09% |
| Measured reactions | 24 |
Point-in-time · zero look-ahead
Half of the 24 BBIO earnings events with a measured close landed between -2.35% and +0.77%; 50% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET | Press release | -1.38% | +0.05% | |
| BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates | Press release | +2.12% | +1.29% | |
| Form 10-Q BridgeBio Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | +2.12% | +1.29% | |
| BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET | Press release | -0.64% | -0.66% | |
| Form 10-K BridgeBio Pharma, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.47% | -5.86% | |
| BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates | Press release | +0.01% | -4.09% | |
| Form 10-Q BridgeBio Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.01% | -4.09% | |
| BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week | Press release | +4.29% | +11.51% | |
| BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates | Press release | -2.47% | +0.70% | |
| Form 10-Q BridgeBio Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | -2.47% | +0.70% | |
| BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET | Press release | +0.72% | -0.22% | |
| BridgeBio Reports First Quarter 2025 Financial Results and Business Updates | Press release | +1.29% | -0.65% | |
| Form 10-Q BridgeBio Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.29% | -0.65% | |
| BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET | Press release | -0.85% | +0.03% | |
| Form 10-K BridgeBio Pharma, Inc. For: Dec 31 | SEC filing · Form 10-K | -2.54% | -2.87% | |
| BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update | Press release | +2.64% | -4.31% | |
| Form 10-Q BridgeBio Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.76% | -6.74% | |
| BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update | Press release | -1.43% | +1.00% | |
| Form 10-Q BridgeBio Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.58% | +7.34% | |
| BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update | Press release | -1.96% | +0.51% | |
| Form 10-Q BridgeBio Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.10% | -2.18% | |
| Form 10-K BridgeBio Pharma, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.15% | -1.02% | |
| BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update | Press release | +0.99% | +0.56% | |
| Form 10-Q BridgeBio Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.45% | +4.57% |
Keep exploring
More BBIO: analyst actions → · SEC filings → · BBIO overview →